Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R L Goode

Showing results (151-160 of 163) with videos related to

Pageof 17
Sort By:
The Prostate. Supplement|January 1, 1996
Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5alpha-reductase inhibitorD M Sutkowski, J E Audia, R L Goode, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 1, 1975
Mutagenic and cytotoxic activity of benzol[a]pyrene 4,5-, 7,8-, and 9,10-oxides and the six corresponding phenolsA W Wood, R L Goode, R L Chang, et al.
Journal of the National Cancer Institute|October 8, 1999
Growth regulation of prostatic stromal cells by prostate-specific antigenD M Sutkowski, R L Goode, J Baniel, et al.
The Journal of Urology|January 1, 1986
Inhibitory effect of warfarin on the metastasis of the PAIII prostatic adenocarcinoma in the ratB L Neubauer, K G Bemis, K L Best, et al.
The Prostate|January 1, 1986
Metastatic spread of the PAIII prostatic adenocarcinoma after implantation in the tail of the ratB L Neubauer, K G Bemis, K L Best, et al.
Thrombosis Research|April 1, 1988
Correlation of the in vivo anticoagulant, antithrombotic, and antimetastatic efficacy of warfarin in the ratG F Smith, B L Neubauer, J L Sundboom, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 1, 1981
Clinical studies with In-111 BLEDTA, a tumor-imaging conjugate of bleomycin with a bifunctional chelating agentD A Goodwin, C F Meares, L H DeRiemer, et al.
Toxicology and Applied Pharmacology|February 1, 1990
Endocrine effects of a new histamine H2-receptor antagonist, nizatidine (LY139037), in the male ratB L Neubauer, R L Goode, K L Best, et al.
The Prostate|January 1, 1993
LY207320 (6-methylene-4-pregnene-3,20-dione) inhibits testosterone biosynthesis, androgen uptake, 5 alpha-reductase, and produces prostatic regression in male ratsB L Neubauer, K L Best, T R Blohm, et al.
The Prostate|October 1, 1995
Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma modelB L Neubauer, K L Best, D F Counts, et al.
Pageof 17

Showing results (151-160 of 163) with videos related to

Sort By:
Pageof 17
The Prostate. Supplement|January 1, 1996
Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5alpha-reductase inhibitorD M Sutkowski, J E Audia, R L Goode, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 1, 1975
Mutagenic and cytotoxic activity of benzol[a]pyrene 4,5-, 7,8-, and 9,10-oxides and the six corresponding phenolsA W Wood, R L Goode, R L Chang, et al.
Journal of the National Cancer Institute|October 8, 1999
Growth regulation of prostatic stromal cells by prostate-specific antigenD M Sutkowski, R L Goode, J Baniel, et al.
The Journal of Urology|January 1, 1986
Inhibitory effect of warfarin on the metastasis of the PAIII prostatic adenocarcinoma in the ratB L Neubauer, K G Bemis, K L Best, et al.
The Prostate|January 1, 1986
Metastatic spread of the PAIII prostatic adenocarcinoma after implantation in the tail of the ratB L Neubauer, K G Bemis, K L Best, et al.
Thrombosis Research|April 1, 1988
Correlation of the in vivo anticoagulant, antithrombotic, and antimetastatic efficacy of warfarin in the ratG F Smith, B L Neubauer, J L Sundboom, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 1, 1981
Clinical studies with In-111 BLEDTA, a tumor-imaging conjugate of bleomycin with a bifunctional chelating agentD A Goodwin, C F Meares, L H DeRiemer, et al.
Toxicology and Applied Pharmacology|February 1, 1990
Endocrine effects of a new histamine H2-receptor antagonist, nizatidine (LY139037), in the male ratB L Neubauer, R L Goode, K L Best, et al.
The Prostate|January 1, 1993
LY207320 (6-methylene-4-pregnene-3,20-dione) inhibits testosterone biosynthesis, androgen uptake, 5 alpha-reductase, and produces prostatic regression in male ratsB L Neubauer, K L Best, T R Blohm, et al.
The Prostate|October 1, 1995
Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma modelB L Neubauer, K L Best, D F Counts, et al.
Pageof 17